EP0412554A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Sustained-release preparation for administration into brain
Assignee: Koken Co Ltd
•
Filing: 1990-08-10
•
Granted: —
•
Expires: 2010-08-10
Abstract
Abstract Use of a pharmaceutically active substance for the treatment of cerebral diseases by administering into the brain a pharmaceutically active substance for the treatment of cerebral diseases in the form of a sustained-release preparation comprising the pharmaceutically active substance incorporated into a biodegradable carrier.
Inventors
- 👤 Toru Hayakawa
- 👤 Toshiki Yoshimine
- 👤 Keiji Fujioka
- 👤 Yoshihiro Takada
- 👤 Yoshio Sasaki
- 👤 Tsunemasa Irie
- 👤 Nobuyuki Fukushima
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-08 10:15
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1808; A61K38/1825; A61K38/185; A61K9/00; A61K9/0012; A61K9/0085; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2063; A61K9/70
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
25 words
A sustained-release preparation for the treatment of cerebral diseases containing a pharmaceutically active substance for the treatment of cerebral diseases incorporated into a biodegradable carrier.
Claim 2
Dependent Claim
25 words
A sustained-release preparation for the treatment of cerebral diseases containing a pharmaceutically active substance for the treatment of cerebral diseases incorporated into a biodegradable carrier.
Claim 3
Dependent Claim
16 words
The preparation of claim 1, wherein said treatment is by administering said preparation into the brain.
Claim 4
Dependent Claim
17 words
The preparation according to claims 1 or 2, wherein said sustained-release preparation is implanted within the brain.
Claim 5
Dependent Claim
17 words
The preparation according to claims 1 or 2, wherein said sustained-release preparation is inserted within the brain.
Claim 6
Dependent Claim
30 words
The preparation according to any one of claims 1 to 4, wherein said active substance is a brain peptide, a derivative thereof, an antibody, an agonist or an antagonist thereof.
Claim 7
Dependent Claim
23 words
The preparation according to any one of claims 1 to 4, wherein said active substance is an antibiotic agent or an anticancer agent.
Claim 8
Dependent Claim
28 words
The preparation according to claim 5, wherein said brain peptide is a neurotrophic factor, a cell growth factor, a neurotransmitter-related compound, an immuno-stimulator or a tumor necrosis factor.
Claim 9
Dependent Claim
29 words
The preparation according to claim 7, wherein said neurotrophic factor is nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), NT-3 or hippocampus-derived neurotrophic factor.
Claim 10
Dependent Claim
14 words
The preparation according to claim 8, wherein said hippocampus-derived neurotrophic factor is hippocampus factor.
Claim 11
Dependent Claim
21 words
The preparation according to claim 7, wherein said cell growth factor is epidermal growth factor (EGF) or fibroblast growth factor (FGF).
Claim 12
Dependent Claim
15 words
The preparation according to claim 7, wherein said neurotransmitter-related compound is cholecystokinin (CCK) or vasopressin.
Claim 13
Dependent Claim
13 words
The preparation according to claim 7, wherein said immuno-stimulator is interleukin or interferon.
Claim 14
Dependent Claim
22 words
The preparation according to any one of claims 1 to 12, wherein said biodegradable carrier is collagen, gelatin or a mixture thereof.
Claim 15
Dependent Claim
12 words
The preparation according to claim 13, wherein said biodegradable carrier is collagen.
Claim 16
Dependent Claim
11 words
The preparation according to claim 13, wherein said collagen is atelocollagen.
Claim 17
Dependent Claim
20 words
The preparation according to any one of claims 1 to 15, wherein said sustained-release preparation is a formed solid preparation.
Claim 18
Dependent Claim
32 words
The preparation according to any one of claims 1-5 and 7-16, wherein said substance for the treatment of cerebral diseases is a substance which is not substantially transferred through the blood-brain barrier.
Claim 19
Dependent Claim
26 words
Use of a pharmaceutically active substance for the treatment of cerebral diseases for the production of a sustained-release preparation according to any one of claims 1-17.
Claim 20
Dependent Claim
45 words
Use of a pharmaceutically active substance for the treatment of cerebral diseases in the form of a sustained-release preparation comprising said pharmaceutically active substance incorporated into a biodegradable carrier for use in the treatment of cerebral diseases by administering the sustained-release preparation into the brain.
Claim 21
Dependent Claim
45 words
Use of a pharmaceutically active substance for the treatment of cerebral diseases in the form of a sustained-release preparation comprising said pharmaceutically active substance incorporated into a biodegradable carrier for use in the treatment of cerebral diseases by administering the sustained-release preparation into the brain.
References Cited (Backward Citations)
WO1988000834A1
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.